Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 35

1.

Immunomodulation via targeted inhibition of antigen receptor signal transduction.

Schade AE, Gonzalez-Stawinski G.

Cardiovasc Hematol Disord Drug Targets. 2008 Mar;8(1):1-6. Review.

PMID:
18336251
2.

T-cell activation through the antigen receptor. Part 1: signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse.

Nel AE.

J Allergy Clin Immunol. 2002 May;109(5):758-70. Review. Erratum in: J Allergy Clin Immunol 2002 Jul;110(1):25.

PMID:
11994696
4.

Sequestration of p56(lck) by gp120, a model for TCR desensitization.

Goldman F, Crabtree J, Hollenback C, Koretzky G.

J Immunol. 1997 Mar 1;158(5):2017-24.

PMID:
9036944
5.
6.

Inactivation of lck and loss of TCR-mediated signaling upon persistent engagement with complexes of peptide:MHC molecules.

Lee JE, Cossoy MB, Chau LA, Singh B, Madrenas J.

J Immunol. 1997 Jul 1;159(1):61-9.

PMID:
9200439
7.

The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation.

Delgado JF, Manito N, Segovia J, Almenar L, Arizón JM, Campreciós M, Crespo-Leiro MG, Díaz B, González-Vílchez F, Mirabet S, Palomo J, Roig E, de la Torre JM.

Transplant Rev (Orlando). 2009 Apr;23(2):69-79. doi: 10.1016/j.trre.2009.01.002. Review.

PMID:
19298938
8.
9.

Neither the LCK nor the FYN kinases are obligatory for IL-2-mediated signal transduction in HTLV-I-infected human T cells.

Mills GB, Arima N, May C, Hill M, Schmandt R, Li J, Miyamoto NG, Greene WC.

Int Immunol. 1992 Nov;4(11):1233-43.

PMID:
1472476
10.

Lck is necessary and sufficient for Fas-ligand expression and apoptotic cell death in mature cycling T cells.

Gonzalez-Garcia A, R-Borlado L, Leonardo E, Merida I, Martinez-A C, Carrera AC.

J Immunol. 1997 May 1;158(9):4104-12.

PMID:
9126969
12.

Ig alpha and Ig beta are functionally homologous to the signaling proteins of the T-cell receptor.

Burkhardt AL, Costa T, Misulovin Z, Stealy B, Bolen JB, Nussenzweig MC.

Mol Cell Biol. 1994 Feb;14(2):1095-103.

13.

Immunosuppression and transplant vascular disease: benefits and adverse effects.

Moien-Afshari F, McManus BM, Laher I.

Pharmacol Ther. 2003 Nov;100(2):141-56. Review.

PMID:
14609717
14.

Differential regulation of accessory mitogenic signaling receptors by the T cell antigen receptor.

Zhang XM, Berland R, Rosoff PM.

Mol Immunol. 1995 Apr;32(5):323-32.

PMID:
7739570
15.
16.

The chemokine and chemokine receptor profile of infiltrating cells in the wall of arteries with cardiac allograft vasculopathy is indicative of a memory T-helper 1 response.

van Loosdregt J, van Oosterhout MF, Bruggink AH, van Wichen DF, van Kuik J, de Koning E, Baan CC, de Jonge N, Gmelig-Meyling FH, de Weger RA.

Circulation. 2006 Oct 10;114(15):1599-607. Epub 2006 Oct 2.

17.

Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases.

McRae BL, Wallace C, Dixon KF, Roux A, Mohan S, Jia Y, Presky DH, Tracey DE, Hirst GC.

Int Immunopharmacol. 2005 Apr;5(4):667-77.

PMID:
15710336
18.

Characteristics of chronic rejection in heart transplantation: important elements of pathogenesis and future treatments.

Suzuki J, Isobe M, Morishita R, Nagai R.

Circ J. 2010 Feb;74(2):233-9. Epub 2009 Dec 14. Review.

19.

Inhibiting the NO pathway with intracoronary L-NAME infusion increases endothelial dysfunction and intimal hyperplasia after heart transplantation.

Perrault LP, Malo O, Bidouard JP, Villeneuve N, Vilaine JP, Vanhoutte PM.

J Heart Lung Transplant. 2003 Apr;22(4):439-51.

PMID:
12681422
20.

Inhibition of tyrosine phosphorylation prevents T-cell receptor-mediated signal transduction.

June CH, Fletcher MC, Ledbetter JA, Schieven GL, Siegel JN, Phillips AF, Samelson LE.

Proc Natl Acad Sci U S A. 1990 Oct;87(19):7722-6.

Supplemental Content

Support Center